Seattle-based medical device company Bardy Diagnostics today announced a $35.5 million funding round led by River Cities Capital Fund. The company makes the Carnation Ambulatory Monitor (CAM), which is a small, lightweight heart monitor that can detect arrhythmia. Bardy said the money would be used to grow its platform by expanding its sales force and monitoring services, as well as to invest in augmented intelligence and visualization technologies. The series B funding round drew new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures and Rex Health Ventures.